Press Releases

Date Title and Summary View
Aug 04, 2015
MacroGenics to Present at the 2015 Wedbush PacGrow Healthcare Conference
Rockville, MD , Aug. 04, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious
Additional Formats
Jul 29, 2015
MacroGenics Announces Date of Second Quarter 2015 Financial Results Conference Call
ROCKVILLE, Md , July 29, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX) today announced that on Wednesday, August 5, 2015 , the Company will release its financial results for the quarter ended June 30, 2015 . The Company's management team will host a conference call discussing the
Additional Formats
Jul 28, 2015
MGD011 Advances Into Clinical Development
—  Triggers $10 million milestone payment from Janssen  —  Fourth DART® molecule to enter the clinic in last 12 months ROCKVILLE, Md. , July 28, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc.  (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative
Additional Formats
Jul 14, 2015
MacroGenics Announces Pricing of Public Offering of Common Stock
ROCKVILLE, Md. , July 14, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious
Additional Formats
Jul 13, 2015
MacroGenics Announces Proposed Public Offering of Common Stock
ROCKVILLE, Md. , July 13, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious
Additional Formats
May 30, 2015
MacroGenics Presents Updated Data from Phase 1 Study of Margetuximab at ASCO Annual Meeting 2015

Data Show Signs of Clinical Activity for Margetuximab in HER2-Expressing Tumors

Additional Formats
May 27, 2015
MacroGenics Preclinical Research on MGD006 DART(R) Molecule Published in Science Translational Medicine
—    MGD006 Enables T Cells to Recognize and Kill Leukemia Cells —     Research Paved the Way for Human Clinical Trials ROCKVILLE, Md. , May 27, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative
Additional Formats
May 13, 2015
MacroGenics Announces Presentation at ASCO Annual Meeting 2015

Company to Present Updated Findings From Its Phase 1 Study of Margetuximab

Additional Formats
May 06, 2015
MacroGenics Provides Update on Corporate Progress and First Quarter 2015 Financial Results
-- Company's third bi-specific DART® molecule, MGD010, in clinical testing -- FDA clears IND for fourth DART, MGD011 - Janssen to initiate clinical testing -- Margetuximab Phase 3 SOPHIA study in metastatic breast cancer to initiate 3Q 2015 ROCKVILLE, Md.
Additional Formats
Apr 29, 2015
MacroGenics Announces Date of First Quarter 2015 Financial Results Conference Call
ROCKVILLE, Md. , April 29, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX) today announced that on Wednesday, May 6, 2015 , the Company will release its financial results for the quarter ended March 31, 2015 . The Company's management team will host a conference call discussing the
Additional Formats
Apr 28, 2015
MacroGenics Announces Participation in Two Investor Conferences in May
ROCKVILLE, Md. , April 28, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious
Additional Formats
Apr 20, 2015
MacroGenics Presents Pre-Clinical Data on its Multivalent DR5 DART at the AACR Annual Meeting
ROCKVILLE, Md. , April 20, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious
Additional Formats
Apr 16, 2015
MacroGenics Announces Presentations at AACR Annual Meeting 2015
ROCKVILLE, Md. , April 16, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious
Additional Formats
Apr 07, 2015
MacroGenics to Present at the 14th Annual Needham Healthcare Conference
Rockville, MD , April 7, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious
Additional Formats
Mar 16, 2015
MacroGenics Initiates Phase 1 Study of MGD010 for the Treatment of Autoimmune Disorders

-- First autoimmune DART(r) to enter the clinic -- MacroGenics to receive $3 million milestone payment from Takeda

Additional Formats
Mar 03, 2015
MacroGenics Provides Update on Corporate Progress and 2014 Financial Results
-- Four oncology molecules in clinical development, including two bi-specific DART® molecules -- Margetuximab Phase 3 SOPHIA study in metastatic breast cancer to initiate 3Q 2015 -- Cash runway extends into 2018 ROCKVILLE, Md. , March 3, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc.
Additional Formats
Mar 02, 2015
MacroGenics to Present at the Roth Capital Partners 27th Annual Growth Stock Conference
MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases, today announced that Scott Koenig , M.D., Ph.D.,
Additional Formats
Feb 24, 2015
MacroGenics Announces Date of Fourth Quarter and Full Year 2014 Financial Results Conference Call
MacroGenics, Inc. (Nasdaq: MGNX) today announced that on Tuesday, March 3, 2015 , the Company will release its financial results for the fourth quarter and full year 2014. The Company's management team will host a conference call discussing the Company's financial results and recent corporate
Additional Formats
Feb 05, 2015
MacroGenics to Present at the Leerink Global Healthcare Conference
MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases, today announced that Scott Koenig , M.D., Ph.D.,
Additional Formats
Jan 27, 2015
MacroGenics Announces Closing of Collaboration and License Agreement with Janssen to Develop MGD011 for Multiple B-Cell Malignancies
MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, today announced the closing of the global collaboration and license agreement for
Additional Formats
Jan 12, 2015
MacroGenics to Present at the 33rd Annual J.P. Morgan Healthcare Conference
MacroGenics , Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases, today announced that Scott Koenig ,
Additional Formats
Dec 22, 2014
MacroGenics Enters Collaboration and License Agreement with Janssen to Develop MGD011 for Multiple B-Cell Malignancies
MacroGenics licenses MGD011 (CD19 x CD3 DART®) to Janssen $50 million upfront license fee paid to MacroGenics , and a $75 million equity investment by Johnson & Johnson Innovation - JJDC, Inc. MacroGenics may elect to fund a portion of late-stage development costs in exchange for a U.S.
Additional Formats
Dec 06, 2014
MacroGenics Announces Presentation of Pre-clinical Data on new DART(r) Candidate MGD011 at 56th Annual Meeting of the American Society of Hematology

Results Support Initiation of Clinical Development of MGD011 in Hematological Malignancies

Additional Formats
Dec 03, 2014
MacroGenics to Present at the Oppenheimer 25th Annual Healthcare Conference
ROCKVILLE, Md. , Dec. 3, 2014 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious
Additional Formats
Nov 12, 2014
MacroGenics to Present at the Stifel 2014 Healthcare Conference
ROCKVILLE, Md., Nov. 12, 2014 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious
Additional Formats